Achieve Life Sciences (ACHV) is trading down at $6.97 (-3.80%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Current price targets from 4 firms average $14.5, median $13, ranging from $12 to $20 — the average is 108% above the current $6.97. Each is tracked to its date and scored the same way a member's call is.
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | $0 | $0 | — | — | — | — | — | — |
| Net income | −$1.23M | −$10.6M | −$12.7M | −$16.4M | −$14.7M | −$33.2M | −$42.4M | −$29.8M | −$39.8M | −$54.6M |
| EPS (diluted) | −$232500.00 | −$8828.00 | −$72.29 | −$39.76 | −$5.42 | −$4.08 | −$4.00 | −$1.50 | −$1.24 | −$1.25 |
| Balance sheet | ||||||||||
| Cash and equivalents | $15.0K | $5.28M | $9.52M | $16.7M | $35.9M | $43.0M | $24.8M | $15.5M | $12.8M | $20.9M |
| Total assets | $3.81M | $9.89M | $19.1M | $21.1M | $40.3M | $47.5M | $30.0M | $19.4M | $38.6M | $41.8M |
| Total liabilities | $3.20M | $2.01M | $3.28M | $3.03M | $3.01M | $19.5M | $21.7M | $20.8M | $17.7M | $20.3M |
| Shareholders' equity | $610.0K | — | $15.8M | $18.1M | $37.3M | $28.0M | $8.30M | −$1.45M | $20.9M | $21.5M |
| Cash flow | ||||||||||
| Operating cash flow | −$202.0K | −$9.11M | −$10.6M | −$15.2M | −$13.5M | −$29.4M | −$37.6M | −$24.5M | −$29.8M | −$49.5M |
| Capital expenditure | $46.0K | — | $46.0K | $53.0K | $17.0K | — | — | $21.0K | — | $3.00K |
| Free cash flow | −$248.0K | — | −$10.7M | −$15.3M | −$13.5M | — | — | −$24.5M | — | −$49.5M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Net income | −$12.5M | −$12.4M | −$12.8M | −$12.7M | −$14.4M | −$14.7M | −$10.2M | −$74.8M |
| EPS (diluted) | −$0.36 | −$0.37 | −$0.37 | −$0.37 | −$0.28 | −$0.23 | −$0.19 | −$0.80 |
| Balance sheet | ||||||||
| Cash and equivalents | $9.54M | $12.8M | $13.0M | $51.9M | $31.9M | $20.9M | $28.1M | $48.0M |
| Total assets | $47.9M | $38.6M | $27.4M | $58.9M | $52.0M | $41.8M | $33.1M | $190.4M |
| Total liabilities | $16.5M | $17.7M | $17.1M | $17.3M | $18.4M | $20.3M | $22.4M | $205.1M |
| Shareholders' equity | $31.4M | $20.9M | $10.3M | $41.7M | $33.6M | $21.5M | $10.7M | −$14.7M |
| Cash flow | ||||||||
| Operating cash flow | −$10.4M | −$9.19M | −$11.1M | −$9.07M | −$11.3M | −$18.0M | −$6.93M | −$10.8M |
From Achieve Life Sciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Achieve Life Sciences in our feed yet.